AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01667640 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: sector irradiation
Description: Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.~A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.~Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.~Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.~Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported.
Study NCT01667640 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: whole brain irradiation
Description: For whole brain radiation the entire brain, the base of the skull and the meninges are included.~Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.~The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented.
Study NCT00624676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipo Hydroxy Acid
Description: Twice a day
Study NCT01714401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol 2,5 mg
Description: 20 min nebulization of 2.5 mg of salbutamol
Study NCT01714401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol 5mg
Description: 20 min nebulization of 5 mg of salbutamol
Study NCT03977493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xeomin
Description: One injection of 2.5 to 40 U in each muscle. Injection repeated after 6 weeks if considered necessary
Study NCT02951806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (S) Slow spinal fentanyl injection
Description: Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
Study NCT02314000 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Precision or Precision Spectra Spinal Cord Stimulator System
Study NCT02314000 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision or Precision Spectra Spinal Cord Stimulator System
Study NCT02133716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expressed breast milk
Description: The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment.
Study NCT02133716 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sucrose 24% oral
Description: The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.~A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment.
Study NCT04371068 — intervention group
Intervention type: BIOLOGICAL
Intervention: Culture of removed prosthesis using DTT
Description: No specific or supplementary intervention is performed among patients. The included patients have scheduled surgery consisting of prosthesis removal or change. Instead of being discarded, the prosthesis which was removed during the surgery was sent to the laboratory using the MicroDTTect system and bacterial culture was performed with the fluid obtained. Results will be then compared to classical culture of periprosthetic tissues (PPT).
Study NCT00591305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: diindolylmethane (DIM)
Description: 3-month DIM
Study NCT00591305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 585 nm pulsed dye laser
Description: once-time PDL
Study NCT00591305 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 585 nm pulsed dye laser
Description: once-time PDL
Study NCT03856242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin Oral Capsule
Description: Tamsulosin Oral Capsule - alpha-1-adrenoblocker for treatment LUTS/BPH 0.4 mg
Study NCT03856242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: Routine transurethral prostatic resection
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ533
Description: s.c.
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to CFZ533
Description: s.c.
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LYS006
Description: p.o.
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to LYS006
Description: p.o.
Study NCT02413229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS1411
Description: DSXS (Taro Pharmaceuticals Inc.)
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAS825
Description: s.c.
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MAS825
Description: s.c.
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOU064 25mg
Description: p.o.
Study NCT02413229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (vehicle) (Taro Pharmaceuticals Inc.)
Study NCT06263192 — intervention group
Intervention type: PROCEDURE
Intervention: Intrauterine insemination
Description: Intrauterine insemination with sperm donors
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOU064 100mg
Description: p.o.
Study NCT02807337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caphosol
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to LOU064
Description: p.o.
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736
Description: s.c.
Study NCT03827798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to VAY736
Description: s.c.
Study NCT01883362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin was supplied in 25mg soft gelatin capsule taken orally twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
Study NCT01883362 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care was not defined per protocol. The investigator prescribed based on the commonly used medications given in the post SCT setting.
Study NCT04330586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide Metered Dose Inhaler [Alvesco]
Description: Ciclesonide 320ug oral inhalation q12h for 14 days
Study NCT04686591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9977 capsule 50 mg
Description: 100 mg dose of AZD9977 capsule 50 mg (as 2 x 50 mg capusles)
Study NCT04686591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
Description: One 100 µg dose of \[14C\]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL)
Study NCT02807337 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,9% NaCl
Study NCT04217954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OXA, 5-FU and bevacizumab plus Toripalimab
Description: 1. concomitant treatment: A. HAIC: oxaliplatin (40 mg/m2 for 2 hours), 5-fluorouracil (800 mg/ m2 for 22 hours) on days 1-3, and arterial bevacizumab 300mg for 2 hours on d1 before oxaliplatin through a percutaneously implanted port-catheter system.~   B. Intravenous PD-1 inhibitor (Toripalimab) 240 mg for 30-60 minutes on d1 before the HAIC.~   The concomitant treatment repeat every three week, up to 6 cycles.~2. Maintenance treatment: Bevacizumab (300mg) + PD-1 inhibitor (Toripalimab 240mg) will be given intravenously, every 3 weeks.
Study NCT00829725 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: screws-internal fixation
Description: 3-4-screws-internal fixation
Study NCT04686591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
Description: One 100 mg dose of \[14C\]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
Study NCT00829725 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TARGON FN
Description: The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented
Study NCT04277286 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey
Description: Behavioral study of patients who are in the Transend Program (compliance in follow-up visits after transfert from pediatric to adult care in the 24 months)
Study NCT03272178 — intervention group
Intervention type: DEVICE
Intervention: Depuy total knee implant
Description: patients from Dr Nunley's clinic will get a Depuy implant
Study NCT03272178 — intervention group
Intervention type: DEVICE
Intervention: Triathlon total knee implant
Description: patients from Dr Barrack's clinic will get a Triathlon implant
Study NCT02509169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAE plus P53 gene
Description: Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
Study NCT02509169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TAE
Description: Trans-catheter embolization
Study NCT03578211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making with decision aids
Description: For obese patients, we use shared decision making with decision aids to help them choose the suitable types of bariatric surgery.
Study NCT03894111 — intervention group
Intervention type: OTHER
Intervention: decesased patients
Description: mortality ratio
Study NCT05306483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular septal defect closure surgery
Description: Ventricular septal defect closure surgery
Study NCT05306483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventricular septal defect closure catheter
Description: Catheter closure of VSD
Study NCT01115153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prophylaxis
Description: single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
Study NCT04466592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promotion of competences of participant involved in the management of the post operative period
Description: The research psychologist will be in touch with the participants for 9 months after the surgery (weekly, biweekly or monthly) in order to help them recovering social and work activities, and dealing with the consequences of the surgery. Specifically, four competences will be promoted (future forethought; context evaluation; consequences of own actions forethought; use of available resources), each relevant to four areas (clinical; familiar; working; daily-activities).
Study NCT01042769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aleglitazar
Description: aleglitazar 150 micrograms po daily
Study NCT01042769 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo control po daily
Study NCT00005811 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan hydrochloride
Description: Given IT
Study NCT00005811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01926574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: long rehabilitation program
Study NCT01926574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: short rehabilitation program
Study NCT01926574 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and commitment therapy (ACT)
Study NCT02505737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TH-CBT
Description: Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
Study NCT02505737 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Community-based treatment as usual and supplemental reading material
Study NCT01705379 — intervention group
Intervention type: BIOLOGICAL
Intervention: Novartis Meningococcal ACWY Conjugate Vaccine
Description: Immunization
Study NCT02335697 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Attitude change towards female circumcision
Description: The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
Study NCT02335697 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study NCT03977493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Concentrate
Description: One injection in each muscle.
Study NCT00822536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin and Clopidogrel
Description: Aspirin \<= 325 mg/j Clopidogrel = 75 mg /j
Study NCT00822536 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin : \<= 325 mg/j
Study NCT01943591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils
Description: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
Study NCT01943591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils
Description: Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
Study NCT02191293 — intervention group
Intervention type: DRUG
Intervention: Viramune® tablets
Study NCT02271347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMX001
Description: CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
Study NCT01308502 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dx-pH probe
Description: Dx-pH probe with 24 hour recording
Study NCT02514902 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral Flow Device
Description: A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
Study NCT03354260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized adapted oral diet and nutritional education
Description: Optimized personalized oral nutrition in ICU and nutritional follow up with therapeutic educational after exit of ICU
Study NCT01133457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finasteride
Description: Finasteride tablets 1 mg
Study NCT01133457 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finasteride
Description: Finasteride tablets 1 mg
Study NCT04296591 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fetal heart doppler findings
Description: Doppler data of main pulmonary artery and right pulmonary artery, mitral valve e/a wave ratio and lamellar body count were determined as the main research parameters. In both groups, fetal thorax and heart circumference ratio, mitral e/a wave ratio, right pulmonary artery and main pulmonary doppler indexes (PI, RI, S / D, AT / ET) were evaluated before cesarean section.
Study NCT03581019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterus transplantation
Description: uterus transplantation from deceased donor
Study NCT02168192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation-Debrief
Description: Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
Study NCT02168192 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Traditional lecture
Description: Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
Study NCT02829580 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Measures by Doppler and study of endothelial function
Study NCT02829580 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Measures by Doppler and study of endothelial function
Study NCT02038244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal integrative medicine inpatient treatment program
Study NCT01384513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT01384513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV
Study NCT01384513 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: 2 Gy administered as part of the conditioning regimen
Study NCT01384513 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Undergo DLI
Study NCT01384513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Given IV
Study NCT01384513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT01384513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Given IV
Study NCT01384513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation
Description: Undergo CD34+ allogeneic PBSCT
Study NCT01384513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood stem cell transplantation (PBSCT)
Description: Undergo CD34+ allogeneic PBSCT
Study NCT01199913 — intervention group
Intervention type: OTHER
Intervention: The intervention will be Mini-Mental Status Examination (MMSE)
Description: A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
Study NCT02931357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid 0.54%
Description: Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
Study NCT02931357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calgel®
Description: Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
Study NCT01832753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levothyroxine
Study NCT01000233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phytine (phytate)
Description: 300 mg tid \* 24 months
Study NCT01000233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Phytine (Phytate)